As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Upadacitinib for moderate-to-severe active rheumatoid arthritis.
This review discusses its pharmacological properties, dosage and administration, efficacy and tolerability, and evidence in support of the use of Upadacitinib as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Associate Professor Andrew Östör, a consultant rheumatologist at Cabrini Medical Centre and researcher at Emeritus Research, Melbourne.
Please login below to download this issue (PDF)